NOVEL POLYPEPTIDE SELECTIVELY BINDING TO HUMAN PROGRAMMED CELL DEATH PROTEIN (PD-1) AND USE THEREOF
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Oct 6, 2022
app pub date -
Aug 21, 2020
filing date -
Aug 23, 2019
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present invention relates to a novel polypeptide which can specifically bind to programmed cell death protein 1, a polynucleotide coding for the polypeptide, a vector comprising the polynucleotide, a recombinant microorganism in which the expression vector has been introduced, a method for preparing the polypeptide by means of the recombinant microorganism, a cancer preventing or treating composition comprising the polypeptide, and a cancer prevention or treatment method comprising administration of the cancer preventing or treating composition comprising the polypeptide. The polypeptide of the present invention can inhibit the activity of programmed cell death protein 1 by binding thereto and thus can be widely utilized for a formulation for preventing or treating various diseases associated with programmed cell death protein 1.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully